GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CARGO Therapeutics
The shares of CARGO, a biotech company developing CAR-T therapy, reflect the potential of its scientific platform. The post-IPO price will depend on the progress of its cancer treatments in clinical trials.
Share prices of companies in the market segment - Oncology cell gene therapy
CARGO Therapeutics is a biopharmaceutical company developing next-generation CAR-T cell-based therapies for cancer treatment. We've categorized it under "Oncology: Cell Therapy." The chart below shows how the market is evaluating innovations in this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
CARGO Therapeutics is a biotech company developing next-generation cell therapy (CAR-T) for cancer treatment. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how CARGO compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
CRGX - Daily change in the company's share price CARGO Therapeutics
CARGO Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in cell therapy companies. This metric is a measure of sensitivity to clinical trial data, serving as a risk assessment element.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
CARGO Therapeutics is a biopharmaceutical company developing next-generation cell therapies for cancer. The cell gene therapy sector is one of the most advanced and volatile in biotech. The chart below reflects average fluctuations in this industry, serving as a benchmark for valuing CRGX stock.
Daily change in the price of a broad market stock, index - GURU.Markets
CARGO Therapeutics is a biotech company working on cell therapy. Its shares are a bet on scientific breakthroughs. Their extreme volatility, driven by research data, is part of the dynamics of the innovation sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CARGO Therapeutics
CARGO Therapeutics' year-to-date performance is a story of next-generation cell therapy development. Its 12-month market cap is entirely dependent on clinical trial data. The success of its CAR-T therapy, which aims to overcome resistance to existing therapies, could offer new hope to patients with blood cancer.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
CARGO, a recent IPO, is a biotech company developing cell therapies for cancer. Its performance reflects investor confidence in its scientific platform. The chart below shows how its high potential and early-stage risks compare to the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
CARGO Therapeutics is a company at the forefront of cell therapy, and its shares are driven by lab news. Its year-over-year performance relative to the market isn't about economics, but rather about hope for a revolution in cancer treatment. Success in trials could boost the stock, demonstrating a complete disconnect from overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CARGO Therapeutics
CARGO is an oncology company developing cell therapy. Being in the clinical stage, its monthly valuation is entirely dependent on news. Trial results confirming the efficacy of its CAR-T therapy are the main driver.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
CARGO Therapeutics is at the forefront of the fight against cancer, developing a new generation of CAR-T cell therapy. The dynamics of the gene therapy sector, as the chart shows, reflect both enormous hopes and high risks. The company's history is one of betting on scientific breakthroughs, where success in clinical trials can not only save lives but also radically change the industry itself.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CARGO Therapeutics is a clinical-stage biopharmaceutical company developing next-generation CAR-T cell therapy for cancer. The company's future depends solely on the success of its clinical trials. The broader market chart serves as just a backdrop to demonstrate how its cutting-edge scientific platform has given its stock a life of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CARGO Therapeutics
CARGO Therapeutics is a clinical-stage biotech company developing CAR-T cell therapy for cancer. Its weekly stock price is extremely volatile and depends entirely on news about the progress of its clinical trials.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
CARGO Therapeutics is a biotech company working in the cutting-edge field of CAR-T cell therapy for cancer treatment. This sector is characterized by high potential and equally high risks. The chart will help you understand whether CARGO's share price movement is related to its own clinical data or a general reaction to news in this field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
CARGO is a biotech company working in cell therapy. Its shares are a pure bet on a scientific breakthrough. The chart clearly shows their extreme volatility and complete dependence on news about clinical trials, not the market.
Market capitalization of the company, segment and market as a whole
CRGX - Market capitalization of the company CARGO Therapeutics
The market capitalization of CARGO Therapeutics, a clinical-stage biotech, reflects investor confidence in its CAR-T therapy platform for cancer treatment. Its high post-IPO valuation is based on promising early data. It represents a high-risk bet that its approach will prove successful in treating complex oncological diseases.
CRGX - Share of the company's market capitalization CARGO Therapeutics within the market segment - Oncology cell gene therapy
CARGO Therapeutics is a clinical-stage biotech company working in cancer cell therapy. Its market share in the pharmaceutical sector is virtually zero. Its market capitalization reflects investors' expectations for a breakthrough in cancer treatment and the future commercial success of its platform, rather than its current business.
Market capitalization of the market segment - Oncology cell gene therapy
The graph below shows the market capitalization of the biotech sector. CARGO Therapeutics is a company at the forefront of cancer cell therapy (CAR-T). Its developments are aimed at addressing the problem of post-treatment relapse. The potential of this market is enormous, and CARGO is striving to develop the next generation of more effective cell-based therapies.
Market capitalization of all companies included in a broad market index - GURU.Markets
CARGO Therapeutics is a biotech company developing next-generation CAR-T cell therapy for cancer treatment. Its market cap is a bet on a breakthrough in this complex field. The chart below shows the economic weight of the advanced cell therapy sector.
Book value capitalization of the company, segment and market as a whole
CRGX - Book value capitalization of the company CARGO Therapeutics
CARGO Therapeutics' book value is derived from its scientific platform and capital for developing next-generation CAR-T cell therapy for cancer treatment. This graph represents a financial benchmark for the biotech company, which is investing in addressing the problem of relapse after existing CAR-T therapy, which requires significant capital.
CRGX - Share of the company's book capitalization CARGO Therapeutics within the market segment - Oncology cell gene therapy
CARGO Therapeutics develops CAR-T cell therapy. The chart shows its share of actual R&D and manufacturing assets. These include its laboratories and sterile manufacturing facilities where personalized "living drugs" are created to fight cancer.
Market segment balance sheet capitalization - Oncology cell gene therapy
CARGO Therapeutics is a biotech company working in cancer cell therapy. Their value lies in their scientific developments. The book value chart shows their R&D base, which is just the tip of the iceberg of their scientific potential in the fight against cancer.
Book value of all companies included in the broad market index - GURU.Markets
CARGO Therapeutics's core assets include cutting-edge laboratories and manufacturing facilities under construction for the development of CAR-T cell therapy. The diagram visualizes how the company is building its physical foundation for producing "living drugs" for cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CARGO Therapeutics
CARGO Therapeutics is a company at the forefront of cancer cell therapy. Its assets are scientific developments, not factories. The chart below visualizes the hope for a medical breakthrough. Its market capitalization is driven by expectations for clinical trials, and its dynamics will indicate how much investors believe in the success of its innovative platform.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
CARGO Therapeutics is a biotech company developing advanced cell therapy (CAR-T) for cancer treatment. Its valuation is based solely on the potential of its scientific platform. The chart demonstrates how much its market capitalization, driven by hopes for medical breakthroughs, exceeds its current tangible assets.
Market to book capitalization ratio for the market as a whole
CARGO Therapeutics is a biotech company specializing in cell therapy. Its valuation is based almost entirely on the prospects of its scientific platforms. This metric demonstrates a huge gap between its market capitalization, which reflects its hopes for a breakthrough in cancer treatment, and its current book value.
Debts of the company, segment and market as a whole
CRGX - Company debts CARGO Therapeutics
CARGO Therapeutics is a clinical-stage biotech developing a new generation of CAR-T cell therapy for cancer. This chart depicts its financial model. The company raised significant capital during its IPO to fund its expensive and complex clinical trials.
Market segment debts - Oncology cell gene therapy
CARGO Therapeutics is a clinical-stage biopharmaceutical company developing a new generation of CAR-T cell therapies for cancer treatment. This is one of the most advanced and expensive areas in medicine. This graph reflects the enormous financial requirements required to advance such complex technologies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CARGO Therapeutics
CARGO Therapeutics is a clinical-stage biotech company working in cell therapy. This chart shows its financial structure. As with most companies in this field, debt is a huge risk. Funding must come from equity to avoid jeopardizing expensive research.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
CARGO Therapeutics is a biotech company developing next-generation cell therapies for cancer. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to fund its cutting-edge and capital-intensive research in one of the most promising areas of oncology.
Debt to book value of all companies in the market
CARGO Therapeutics is a clinical-stage biotech company specializing in cancer cell therapy. This is one of the most advanced, but also most expensive, areas of medicine. This graph of total market debt serves as an indicator of investor risk appetite, which directly impacts the company's ability to fund its breakthrough research.
P/E of the company, segment and market as a whole
P/E - CARGO Therapeutics
CARGO Therapeutics is a clinical-stage biotech developing a new generation of CAR-T cell therapy for cancer. This chart reflects the high, yet risky, expectations of investors in advanced oncology. The dynamics depend entirely on the results of clinical trials and confidence in the potential of their platform.
P/E of the market segment - Oncology cell gene therapy
CARGO Therapeutics is a clinical-stage biotech company developing a new generation of CAR-T cell therapy for cancer. Their approach is aimed at overcoming resistance to existing treatments. This chart shows the average valuation for the oncology sector, reflecting investor expectations for a breakthrough in personalized cell therapy.
P/E of the market as a whole
CARGO Therapeutics is a biotech company developing cell therapy (CAR-T) for cancer treatment. Its valuation is a pure bet on the success of this complex and personalized technology. It is in no way tied to the general economic cycles illustrated by this chart. Its fate is decided in clinics and the minds of regulators.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CARGO Therapeutics
CARGO Therapeutics is a biotech company developing next-generation CAR-T cell therapy for cancer. This chart reflects investors' confidence in the potential of its scientific developments. Future profits are entirely dependent on the success of clinical trials and the ability to offer a more effective treatment than existing therapies.
%20P%2FE%20CARGO%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CARGO-Therapeutics&v=1772689518602 "Chart of the company's future (projected) P/E CARGO Therapeutics")
Future (projected) P/E of the market segment - Oncology cell gene therapy
CARGO Therapeutics is a clinical-stage biotechnology company developing a new generation of CAR-T cell therapy for cancer. The chart reflects average expectations for the oncology segment. CRGX's position relative to this benchmark reflects investors' bet on their ability to create more effective and safe cell therapies for cancer patients.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772689518603 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
CARGO Therapeutics is a clinical-stage biotechnology company developing a new generation of CAR-T cell therapy for the treatment of blood cancers. The company aims to overcome the limitations of existing treatments. This chart of overall market expectations serves as a barometer of investor appetite for funding cutting-edge, yet high-risk, oncology research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772689518604 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CARGO Therapeutics
CARGO Therapeutics is a clinical-stage biotechnology company developing a new generation of CAR-T cell therapy for cancer treatment. Its financial schedule currently consists of research and development expenses. Potential profitability is entirely dependent on success in developing more effective and safe cell therapy.
Profit of companies in the market segment - Oncology cell gene therapy
CARGO Therapeutics is a clinical-stage biotechnology company developing a new generation of CAR-T cell therapy for cancer treatment. Its goal is to overcome the limitations of existing methods. This chart shows the overall profitability of the cell-based gene therapy oncotherapy sector, reflecting the massive investment and scientific excitement surrounding one of the most cutting-edge fields in modern medicine.
Overall market profit
CARGO Therapeutics is a clinical-stage biotech developing CAR-T cell therapy for cancer. Its value and prospects are entirely dependent on the success of its research. The overall market situation, as illustrated by this chart, is critical for attracting the massive investment required to conduct costly clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CARGO Therapeutics
CARGO Therapeutics is a clinical-stage biotechnology company developing a new generation of CAR-T cell therapy for cancer treatment. Future profits are entirely dependent on the success of its developments. This chart reflects analysts' speculative expectations regarding the potential of its innovative approaches to cancer treatment.
%20profit%20of%20the%20company%20CARGO%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CARGO-Therapeutics&v=1772689518609 "Graph of future (projected) profit of the company CARGO Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
CARGO Therapeutics is a biotech company developing a new generation of CAR-T cell therapy for the treatment of oncology. Its goal is to overcome the limitations of existing methods. Its future depends on the success of clinical trials. This chart reflects forecasts for the entire biotech sector, providing context for assessing CARGO's potential and risks in this cutting-edge field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772689518616 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
CARGO Therapeutics is a biotechnology company focused on cell therapy for cancer treatment. Its prospects depend entirely on clinical development success. The overall economic indicators presented in this chart are not directly related to its current operating performance.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772689518618 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CARGO Therapeutics
CARGO Therapeutics is a clinical-stage biotech company working in the cutting-edge field of cancer cell therapy. While revenue is absent, its valuation, as measured here, is based entirely on its scientific potential. This is a bet by investors that its developments will lead to the creation of a new, effective cancer treatment.
P/S market segment - Oncology cell gene therapy
CARGO Therapeutics is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for cancer treatment. Future revenue depends on the success of its innovative developments. This oncology chart reflects investor expectations for CARGO Therapeutics' potential to improve existing cell therapies.
P/S of the market as a whole
CARGO Therapeutics is a clinical-stage biotechnology company developing a new generation of CAR-T cell therapies for cancer treatment. The company aims to overcome the limitations of existing treatments. This market revenue valuation chart helps understand how investors value the company's potential to achieve the next breakthrough in cellular immuno-oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CARGO Therapeutics
CARGO Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR-T cell therapies for cancer treatment. This chart shows how the market assesses the future commercial potential of its innovative treatments, based on their efficacy and success in clinical trials.
%20P%2FS%20CARGO%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CARGO-Therapeutics&v=1772689518635 "The graph of the company's future (projected) P/S CARGO Therapeutics")
Future (projected) P/S of the market segment - Oncology cell gene therapy
CARGO Therapeutics is a clinical-stage biotechnology company developing a new generation of CAR-T cell therapy for cancer treatment. The company's valuation is based on investors' belief in its scientific approach, which aims to overcome the limitations of existing cell therapy methods, promising enormous, but highly risky, potential.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772689518638 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
CARGO Therapeutics is a biotechnology company developing next-generation cell therapies for cancer treatment. This is one of the most advanced areas of science. Revenue growth projections presented here do not reflect the potential of such revolutionary treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772689518649 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CARGO Therapeutics
CARGO Therapeutics is a clinical-stage biotech company specializing in CAR-T cell therapy for cancer treatment. It currently has no commercial products and, therefore, no sales revenue. Any revenue shown in the chart is likely from partnerships.
Sales of companies in the market segment - Oncology cell gene therapy
CARGO Therapeutics (CRGO) is a biotechnology company developing a new generation of CAR-T cell therapy for cancer treatment. Its goal is to overcome resistance mechanisms to existing treatments. This metric reflects revenue in the oncotherapy cell therapy sector. CARGO operates at the cutting edge of science, striving to improve outcomes for cancer patients.
Overall market sales
CARGO Therapeutics is a biotechnology company developing CAR-T cell therapy for cancer treatment. Its growth depends on scientific advances and significant investment. This graph, reflecting the state of financial markets, affects the availability of capital. During periods of growth, investors are more inclined to fund breakthrough but capital-intensive medical technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CARGO Therapeutics
CARGO Therapeutics is a biotechnology company developing next-generation CAR-T cell therapies for cancer treatment. Its future revenue is entirely dependent on the success of clinical trials and the commercialization of its innovative approaches. This chart reflects analyst forecasts, which are essentially a bet on the scientific and commercial potential of its cutting-edge oncology platform.
%20sales%20of%20the%20company%20CARGO%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CARGO-Therapeutics&v=1772689518654 "Schedule of future (projected) sales of the company CARGO Therapeutics")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
CARGO Therapeutics is a clinical-stage biotechnology company specializing in the development of CAR-T cell therapies for the treatment of cancer. This forecast chart reflects the potential future revenue of their lead candidates. This is an analyst's perspective on the commercial prospects of this cutting-edge cancer treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772689518656 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
CARGO Therapeutics is a biotech company developing next-generation cell therapy (CAR-T) for cancer treatment. It aims to address the problem of relapse after existing therapies. This chart illustrates the overall investment climate, but for CARGO, the key is a scientific breakthrough that could bring hope to patients with the most complex forms of blood cancer.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772689518658 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CARGO Therapeutics
CARGO Therapeutics is a clinical-stage biotechnology company developing a new generation of CAR-T cell therapy for cancer treatment. Its financial performance reflects significant investments in cutting-edge science. The chart shows its current profitability, which is an investment in the development of potentially breakthrough cancer treatments.
Market segment marginality - Oncology cell gene therapy
CARGO Therapeutics is a clinical-stage biotech developing a new generation of CAR-T cell therapy for cancer. This chart reflects its operating expenses. Like other biotechs in this space, the path to profitability is long and requires significant investment in research and clinical trials.
Market marginality as a whole
CARGO Therapeutics is a clinical-stage biotech developing CAR-T cell therapy for cancer. Its operations require significant investment. This total return chart reflects market sentiment. During periods of economic optimism, investors are more willing to fund capital-intensive and breakthrough technologies in oncology.
Employees in the company, segment and market as a whole
Number of employees in the company CARGO Therapeutics
CARGO Therapeutics is a cutting-edge cell therapy biotechnology company developing CAR T-cell cancer treatments. This is a highly complex area of medicine. This graph shows the growing team of scientists and clinicians working to create personalized living drugs to combat cancer.
Share of the company's employees CARGO Therapeutics within the market segment - Oncology cell gene therapy
CARGO Therapeutics is a biotech company at the forefront of medicine, developing cell therapies for cancer treatment. This is a highly complex, science-intensive field. This chart reflects its investment in human capital, showing the team of leading scientists it has assembled to advance personalized medicine and create "living drugs."
Number of employees in the market segment - Oncology cell gene therapy
CARGO Therapeutics is a biotech company working in the field of CAR-T cell therapy for cancer treatment. This chart, showing employment in the cell and gene oncology sector, illustrates how cutting-edge and rapidly growing this field is. For CARGO, the growing number of specialists reflects both the recognition of this technology and the intense competition for talent and patents.
Number of employees in the market as a whole
CARGO Therapeutics is at the forefront of medicine, developing next-generation cell therapies for cancer. Funding for such breakthrough, yet capital-intensive, research is only possible in a strong economic environment. The growth in overall employment, reflected in this chart, is a sign of such an environment, which is conducive to attracting investment in the most advanced areas of biotechnology.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CARGO Therapeutics (CRGX)
CARGO Therapeutics (CRGX) operates at the forefront of medicine, focusing on cell and gene therapy for oncology. This chart, for such a business, represents a near-pure intellectual capital valuation. Market value reflects the company's hopes for a revolutionary treatment. Value is created by the R&D team, and it bears no correlation to its size.
%20of%20the%20company%20CARGO%20Therapeutics%20(CRGX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CARGO-Therapeutics-CRGX&v=1772689518697 "Chart of market capitalization per employee (in thousands of dollars) of the company CARGO Therapeutics (CRGX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
CARGO Therapeutics is a biotechnology company focused on cancer cell therapy, one of the most advanced fields in medicine. Its extremely high market capitalization per employee reflects investors' belief that its scientific platform has the potential to revolutionize cancer treatment.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772689518698 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
CARGO Therapeutics is a biotech company developing CAR-T cell therapy for cancer treatment. This is one of the most advanced areas in oncology. This chart for CARGO illustrates how the cost per employee in the cell therapy field can be astronomical, reflecting the complexity of the technology and the hope of curing the most severe forms of cancer.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772689518699 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CARGO Therapeutics (CRGX)
CARGO Therapeutics is a clinical-stage biotech company working in the cutting-edge, but extremely expensive, field of cell therapy (CAR-T). The company is profitless. This chart shows an astronomical loss per employee, reflecting the colossal costs of R&D and customized manufacturing in this field.
%20Chart%20CARGO%20Therapeutics%20(CRGX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CARGO-Therapeutics-CRGX&v=1772689518700 "Company Profit Per Employee (in thousands of dollars) Chart CARGO Therapeutics (CRGX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
CARGO Therapeutics is a biotechnology company focused on cell therapy for cancer treatment. The productivity of each scientist in this cutting-edge field is critical to success. This chart shows the potential value each employee creates, which is an indicator of the effectiveness of R&D investments.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772689518701 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
CARGO Therapeutics is a biotech company developing a new generation of CAR-T cell therapy for cancer treatment. This is cutting-edge, personalized medicine. This chart, showing the market average profit per employee, provides important context. It illustrates how high the stakes are in biotech, where a single successful therapy can generate colossal profits per scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772689518701 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CARGO Therapeutics (CRGX)
CARGO Therapeutics is a clinical-stage biotech company developing CAR-T cell therapy for cancer. Since it doesn't yet have commercial products, it has no revenue per employee. This graph clearly illustrates the R&D phase, where the team is focused entirely on conducting clinical trials for its innovative treatments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CARGO-Therapeutics-CRGX&v=1772689518706 "Sales chart per company employee CARGO Therapeutics (CRGX)")
Sales per employee in the market segment - Oncology cell gene therapy
CARGO Therapeutics (CRGX) is a clinical-stage biotech company specializing in the development of CAR-T cell therapy for cancer. This chart shows the average revenue per employee in the sector. It is important for assessing the efficiency of capital utilization and personnel structure compared to other biotech companies in the cell therapy field.
Sales per employee for the market as a whole
CARGO Therapeutics (CRGX) is at the forefront of medicine, developing next-generation cell therapies (CAR-T) for cancer treatment. Like many clinical-stage biotechs, the company currently has no commercial revenue. This near-zero figure reflects ongoing investment in its team of highly skilled scientists conducting expensive research, building future potential.
Short shares by company, segment and market as a whole
Shares shorted by company CARGO Therapeutics (CRGX)
CARGO Therapeutics (CRGX) is a recent IPO biotech company operating in the highly competitive and complex field of CAR-T cell therapy for cancer treatment. This chart shows short interest. The high short bets reflect the enormous risks: investors doubt CRGX's therapy will be superior to existing ones or are concerned about the extreme complexity and cost of CAR-T manufacturing. (346)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CARGO-Therapeutics-CRGX&v=1772689518710 "Short Shares Chart for the Company CARGO Therapeutics (CRGX)")
Shares shorted by market segment - Oncology cell gene therapy
CARGO Therapeutics (CRGX) is a biotech company working in the cutting-edge field of CAR-T cell therapy for cancer treatment. The chart below shows the overall short position in the gene therapy sector. It illustrates investors' concerns about the manufacturing complexity and high cost of these treatments.
Shares shorted by the overall market
CARGO Therapeutics is a biotech company working at the cutting edge of science (CAR-T therapy). This requires complex and expensive R&D. This chart illustrates the general market "fear." When investors panic, they are unwilling to fund such long-term research projects. They see their cash being burned through and sell off their shares, fearing they'll run out of money.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CARGO Therapeutics (CRGX)
CARGO Therapeutics (CRGX) is a clinical-stage biotech company specializing in CAR-T cell therapy for cancer treatment. This is one of the most advanced, but also expensive, areas of oncology. This oscillator measures sentiment, indicating when investor enthusiasm (above 70) or disappointment (below 30) about the data peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CARGO-Therapeutics-CRGX&v=1772689518716 "RSI 14 indicator chart for the company's stock CARGO Therapeutics (CRGX)")
RSI 14 Market Segment - Oncology cell gene therapy
CARGO Therapeutics is a biotech company developing next-generation CAR-T cell therapy for the treatment of blood cancer (lymphoma). This chart measures the collective excitement in the cell therapy sector. It helps determine whether the entire speculative segment is overheated by expectations.
RSI 14 for the overall market
For CARGO Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the cash spigot is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CRGX (CARGO Therapeutics)
CARGO Therapeutics is a biotech company developing a next-generation cell therapy (CAR-T) for the treatment of blood cancers, particularly for patients who have relapsed after their first CAR-T therapy. This chart shows the speculative average price target from analysts based on their belief in this cutting-edge R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CRGX-CARGO-Therapeutics&v=1772689518732 "A chart showing analyst consensus forecasts for the expected stock price. CRGX (CARGO Therapeutics)")
The difference between the consensus estimate and the actual stock price CRGX (CARGO Therapeutics)
CARGO Therapeutics is a biotech company developing the next generation of CAR-T cell therapy for cancer. This chart shows the growth potential analysts see. It measures the gap between the price and the forecast, reflecting their belief that their technology can overcome resistance to existing CAR-T therapies.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CRGX-CARGO-Therapeutics&v=1772689518734 "A chart showing the difference between the consensus forecast and the actual stock price. CRGX (CARGO Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
CARGO Therapeutics is a cutting-edge R&D company developing next-generation cell therapies (CAR-T) for cancer treatment. This chart shows analysts' overall expectations for the entire oncotherapy cell therapy sector. It reflects whether experts believe in the commercial success of "living drugs" or consider the entire industry too expensive.
Analysts' consensus forecast for the overall market share price
CARGO Therapeutics is a biotech company developing next-generation cell therapies (CAR-T) for cancer treatment, particularly for patients who have failed existing treatments. This chart reflects the overall market "risk appetite." For CRGX, which operates in one of the most advanced and expensive areas of medicine, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CARGO Therapeutics
CARGO Therapeutics is a biotech R&D company working in the hot field of cell therapy. They are developing a next-generation CAR-T therapy (for blood cancers) that should overcome resistance to existing CAR-T therapies. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline.
AKIMA Market Segment Index - Oncology cell gene therapy
CARGO Therapeutics is a cell-based gene therapy company specializing in oncology. They develop CAR-T therapy, which reprograms a patient's immune cells to attack cancer. This is at the cutting edge of medicine. This chart compares their composite index to the sector, showing how their cutting-edge, yet expensive, technology stacks up against other biotechs.
The AKIM Index for the overall market
CARGO Therapeutics is a biotech company developing next-generation CAR-T cell therapy for the treatment of cancer (lymphoma). This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical for funding this cutting-edge platform.
